Effect of Mesenchymal Stromal Cells on Sepsis and Septic Shock - Trial NCT05283317
Access comprehensive clinical trial information for NCT05283317 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by TC Erciyes University and is currently Completed. The study focuses on Sepsis,Septic Shock. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
TC Erciyes University
Timeline & Enrollment
Phase 1/2
Mar 11, 2018
Nov 13, 2019
Primary Outcome
Mortality
Summary
Methods:Ten patients were enrolled in the study. Adipose derived-MSCs infusions were given
 (1x 106/ kg, on 1st, 3rd, 5th, 7th and 9th days of therapy) together with Standard therapy.
 Before the MSCs applications, blood samples were collected for cytokine assessment (TNF-ฮฑ,
 IFN-ฮณ, IL-2, IL-4, IL-6, IL-10). The clinical and laboratory improvements were recorded and
 compared with control groups selected retrospectively.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05283317
Non-Device Trial